US20020110841A1 - Regulation of cell growth by MUC1 - Google Patents

Regulation of cell growth by MUC1 Download PDF

Info

Publication number
US20020110841A1
US20020110841A1 US10/032,786 US3278601A US2002110841A1 US 20020110841 A1 US20020110841 A1 US 20020110841A1 US 3278601 A US3278601 A US 3278601A US 2002110841 A1 US2002110841 A1 US 2002110841A1
Authority
US
United States
Prior art keywords
muc1
cancer
test agent
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/032,786
Other languages
English (en)
Inventor
Donald Kufe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Priority to US10/032,786 priority Critical patent/US20020110841A1/en
Assigned to DANA-FARBER CANCER INSTITUTE, INC. reassignment DANA-FARBER CANCER INSTITUTE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KUFE, DONALD W.
Publication of US20020110841A1 publication Critical patent/US20020110841A1/en
Priority to US10/733,212 priority patent/US7745109B2/en
Assigned to NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR reassignment NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: DANA-FARBER CANCER INSTITUTE
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
US10/032,786 2000-12-22 2001-12-26 Regulation of cell growth by MUC1 Abandoned US20020110841A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/032,786 US20020110841A1 (en) 2000-12-22 2001-12-26 Regulation of cell growth by MUC1
US10/733,212 US7745109B2 (en) 2000-12-22 2003-12-11 Regulation of cell growth by MUC1

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25759000P 2000-12-22 2000-12-22
US30830701P 2001-07-27 2001-07-27
US10/032,786 US20020110841A1 (en) 2000-12-22 2001-12-26 Regulation of cell growth by MUC1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/733,212 Division US7745109B2 (en) 2000-12-22 2003-12-11 Regulation of cell growth by MUC1

Publications (1)

Publication Number Publication Date
US20020110841A1 true US20020110841A1 (en) 2002-08-15

Family

ID=26946058

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/032,786 Abandoned US20020110841A1 (en) 2000-12-22 2001-12-26 Regulation of cell growth by MUC1
US10/733,212 Expired - Fee Related US7745109B2 (en) 2000-12-22 2003-12-11 Regulation of cell growth by MUC1

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/733,212 Expired - Fee Related US7745109B2 (en) 2000-12-22 2003-12-11 Regulation of cell growth by MUC1

Country Status (6)

Country Link
US (2) US20020110841A1 (fr)
EP (2) EP1958642A1 (fr)
JP (1) JP4276432B2 (fr)
AU (1) AU2002246791C1 (fr)
CA (1) CA2432276A1 (fr)
WO (1) WO2002058450A2 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
US20040166543A1 (en) * 2000-12-22 2004-08-26 Dana-Farber Cancer Institute, Inc., A Boston Corporation Regulation of cell growth by MUC1
US20050042209A1 (en) * 2000-09-11 2005-02-24 KUFE Donald W. MUC1 extracellular domain and cancer treatment compositions and methods derived therefrom
US20070202134A1 (en) * 2004-02-23 2007-08-30 Kufe Donald W Muc1 Antagonist Enhancement of Death Receptor Ligand-Induced Apoptosis
US20080090770A1 (en) * 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction
US20080107661A1 (en) * 2006-07-28 2008-05-08 Dana-Farber Cancer Institute, Inc. MUC1 and ABL
US20080241125A1 (en) * 2006-07-20 2008-10-02 Kufe Donald W Muc1-ikb kinase complexes and their activities
US20080286264A1 (en) * 2005-02-15 2008-11-20 Dana-Farber Cancer Institute, Inc. Modulation of Muc1 Activity
US20090087437A1 (en) * 2007-02-02 2009-04-02 Kufe Donald W Methods and compositions relating to the regulation of apoptosis by muc1 and bh3-containing proapoptotic proteins
US20090136520A1 (en) * 2005-08-22 2009-05-28 Kufe Donald W Mitochondrial localization of muc1
US20100047829A1 (en) * 2006-11-28 2010-02-25 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
US20100098683A1 (en) * 2006-12-08 2010-04-22 Dana-Farber Cancer Institute, Inc. MUC1 and Galectin-3
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US8012695B2 (en) 2007-02-14 2011-09-06 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by MUC1 and KLF proteins
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
JP2007502119A (ja) * 2003-08-14 2007-02-08 エクセリクシス， インク． βカテニン経路のモディファイヤーとしてのＵＰｓ及び使用方法
JP2008528623A (ja) * 2005-01-28 2008-07-31 ラモット アット テル アビブ ユニバーシティ， リミテッド 抗ＭＵＣ１のα／β抗体
CN101232895B (zh) 2005-04-15 2014-06-04 亚利桑那癌症治疗公司 用于治疗转移性癌症的治疗肽
US20080311575A1 (en) * 2005-05-26 2008-12-18 Kufe Donald W Modulation of Muci-Dependent Anti-Estrogen Resistance
JP2011512415A (ja) * 2008-02-20 2011-04-21 アリゾナ バイオメディカル リサーチ コミッション 癌の治療および予防のための治療用ペプチドの使用
AU2009305550B2 (en) * 2008-10-17 2014-06-12 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
CN102665748A (zh) 2009-05-27 2012-09-12 达娜-法勃肿瘤研究所公司 使用muc1拮抗剂抑制炎症
WO2012051247A2 (fr) 2010-10-12 2012-04-19 Arizona Biomedical Research Commission Peptides basés sur l'egfr
CA2873632A1 (fr) * 2012-05-16 2013-11-21 Expression Pathology, Inc. Methode srm/mrm pour sous-typage histologique des tumeurs pulmonaires
WO2016161440A2 (fr) 2015-04-03 2016-10-06 Arizona Cancer Therapeutics, Llc Peptides inhibiteurs à base d'egfr pour l'inactivation combinatoire de l'erbb 1, de l'erbb 2 et de l'erbb3

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658992A (en) * 1900-04-17 1900-10-02 Frank A Miller Utensil-handle.
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US5080898A (en) * 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
IT1203672B (it) * 1982-05-12 1989-02-15 Harvard College Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
ATE160361T1 (de) 1987-01-07 1997-12-15 Imp Cancer Res Tech Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose
US6054438A (en) * 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5053489A (en) * 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4963484A (en) * 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8929097D0 (en) 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
DE69329643T2 (de) * 1992-04-13 2001-03-01 Dana Farber Cancer Inst Inc Gegen karzinom-assoziierte antigene gerichtete antikörper
EP0671926B1 (fr) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Peptides immunomodulateurs
WO1994016057A1 (fr) 1992-12-31 1994-07-21 Dana-Farber Cancer Institute, Inc. Sequence amplificatrice modulant l'expression dans les cellules epitheliales
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
GB9404270D0 (en) * 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
DE69532127T2 (de) * 1994-07-20 2004-08-26 Genetics Institute, Inc., Cambridge Interaktions-fullensysteme zum nachweis von protein-interaktionen
IL110464A0 (en) * 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
EP0694808B1 (fr) * 1994-07-29 2001-12-05 Dainippon Ink And Chemicals, Inc. Procédé de formation d'images négatives à très haut contraste et matériau photographique à l'halogénure d'argent et développateur utilisé pour celui-ci
JPH08176138A (ja) * 1994-12-19 1996-07-09 Mercian Corp イソクマリン誘導体
US6074841A (en) * 1996-08-19 2000-06-13 Millennium Biotherapeutics, Inc. Don-1 gene and polypeptides and uses therefor
US5851775A (en) * 1997-03-20 1998-12-22 Johns Hopkins University β-catenin, Tcf-4, and APC interact to prevent cancer
ATE338768T1 (de) * 1997-10-31 2006-09-15 Biomira Inc Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
CA2357015A1 (fr) * 1998-02-21 1999-08-26 Max-Delbruck-Centrum Fur Molekulare Medizin Moyen de traitement de pathologies humaines a partir de la .beta.-catenine, et son utilisation
IT1303683B1 (it) 1998-10-30 2001-02-23 Menarini Ricerche Spa Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica.
WO2000034468A2 (fr) 1998-12-11 2000-06-15 Biomira Inc. Antagonistes de la muc-1 et methodes de traitement de troubles immunitaires
DE60016189T2 (de) 1999-03-26 2005-12-22 Firmenich S.A. Cyklische verbindungen sowie deren verwendung als vorstufen von duftalkoholen
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2000077031A2 (fr) 1999-06-15 2000-12-21 University Health Network Ligands muc1
ES2239032T3 (es) 1999-08-18 2005-09-16 Altarex Medical Corp. Anticuerpo terapeutico contra el antigeno muc-1 y metodos para su uso.
DE60030450T2 (de) 1999-09-08 2007-08-30 Transgene S.A. Von MUC-1 abgeleitete Peptide
US6210289B1 (en) 1999-11-12 2001-04-03 Labrake James Golf grip hand alignment device in combination with a golf club grip
EP1257565A4 (fr) 2000-02-01 2005-04-06 Austin Research Inst Antigenes derives de mucine-1 et leur utilisation en immunotherapie
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
WO2002022685A2 (fr) * 2000-09-11 2002-03-21 Kufe Donald W Domaine extracellulaire du muc1 et compositions et procedes pour le traitement du cancer derives de celui-ci
AU2002215354A1 (en) 2000-10-13 2002-04-22 Arbor Vita Corporation Molecular interactions in hematopoietic cells
EP1958642A1 (fr) 2000-12-22 2008-08-20 Dana-Farber Cancer Institute Régulation de croissance cellulaire par MUC1
US20040209832A1 (en) * 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
AU2002321903A1 (en) 2001-08-03 2003-02-24 Arbor Vita Corporation Molecular interactions in cells
US6716627B2 (en) * 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
JP2005530493A (ja) 2002-04-22 2005-10-13 レコファーマ アーベー ムチン融合ポリペプチドワクチン、組成物およびそれらの使用方法
US20080090770A1 (en) 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042209A1 (en) * 2000-09-11 2005-02-24 KUFE Donald W. MUC1 extracellular domain and cancer treatment compositions and methods derived therefrom
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
US20040166543A1 (en) * 2000-12-22 2004-08-26 Dana-Farber Cancer Institute, Inc., A Boston Corporation Regulation of cell growth by MUC1
US7745109B2 (en) 2000-12-22 2010-06-29 Dana-Farber Cancer Insitute, Inc. Regulation of cell growth by MUC1
US20080090770A1 (en) * 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
US20070202134A1 (en) * 2004-02-23 2007-08-30 Kufe Donald W Muc1 Antagonist Enhancement of Death Receptor Ligand-Induced Apoptosis
US7931904B2 (en) 2005-02-15 2011-04-26 Dana Farber Cancer Institute, Inc. Modulation of MUC1 activity
US20080286264A1 (en) * 2005-02-15 2008-11-20 Dana-Farber Cancer Institute, Inc. Modulation of Muc1 Activity
US20090136520A1 (en) * 2005-08-22 2009-05-28 Kufe Donald W Mitochondrial localization of muc1
US8017315B2 (en) * 2005-08-22 2011-09-13 Dana Farber Cancer Institute, Inc. Mitochondrial localization of MUC1
US8129345B2 (en) 2006-07-20 2012-03-06 Dana-Farber Cancer Institute, Inc. MUC1-IκB kinase complexes and their activities
US20080241125A1 (en) * 2006-07-20 2008-10-02 Kufe Donald W Muc1-ikb kinase complexes and their activities
US20080107661A1 (en) * 2006-07-28 2008-05-08 Dana-Farber Cancer Institute, Inc. MUC1 and ABL
US20100047829A1 (en) * 2006-11-28 2010-02-25 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
US10365283B2 (en) 2006-11-28 2019-07-30 Daiichi Sankyo Europe Gmbh Activated HER3 as a marker for predicting therapeutic efficacy
US20100098683A1 (en) * 2006-12-08 2010-04-22 Dana-Farber Cancer Institute, Inc. MUC1 and Galectin-3
US8420591B2 (en) 2006-12-08 2013-04-16 Dana-Farber Cancer Institute, Inc. MUC1 and galectin-3
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US20110171228A1 (en) * 2007-02-02 2011-07-14 Kufe Donald W Methods and Compositions Relating to the Regulation of Apoptosis by MUC1 and BH3-Containing Proapoptotic Proteins
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US20090087437A1 (en) * 2007-02-02 2009-04-02 Kufe Donald W Methods and compositions relating to the regulation of apoptosis by muc1 and bh3-containing proapoptotic proteins
US8012695B2 (en) 2007-02-14 2011-09-06 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by MUC1 and KLF proteins

Also Published As

Publication number Publication date
EP1531842A4 (fr) 2007-03-07
JP2005510200A (ja) 2005-04-21
EP1958642A1 (fr) 2008-08-20
EP1531842A2 (fr) 2005-05-25
US20040166543A1 (en) 2004-08-26
WO2002058450A3 (fr) 2005-03-24
CA2432276A1 (fr) 2002-08-01
AU2002246791B2 (en) 2007-08-09
US7745109B2 (en) 2010-06-29
AU2002246791C1 (en) 2008-04-03
WO2002058450A2 (fr) 2002-08-01
JP4276432B2 (ja) 2009-06-10

Similar Documents

Publication Publication Date Title
US7745109B2 (en) Regulation of cell growth by MUC1
AU2002246791A1 (en) Regulation of cell growth by MUC1
US10139394B2 (en) Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase
Baruch et al. The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein
JP4351896B2 (ja) ｐ３８／ＪＴＶ−１を有効成分とする癌治療用薬学的組成物及び癌治療用薬学的組成物のスクリーニング方法
Maroni et al. RETRACTED: Hypoxia induced E-cadherin involving regulators of Hippo pathway due to HIF-1α stabilization/nuclear translocation in bone metastasis from breast carcinoma
Kwok et al. Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells
KR20070091602A (ko) ｐ53-의존성 및 비의존성 종양 억제 매개체로서의ＡＲＦ-ＢＰ1 및 그의 용도
Kawano et al. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells
Kikuchi et al. Identification of AMSH-LP containing a Jab1/MPN domain metalloenzyme motif
US20040028684A1 (en) Cancer diagnosis and assays for screening anti-cancer agents
Yang et al. Nucleolin binds to the proliferating cell nuclear antigen and inhibits nucleotide excision repair
Wang et al. Coexpression of MAST205 inhibits the activity of Na+/H+ exchanger NHE3
Suzuki et al. Reduction of caveolin-1 expression in tumorigenic human cell hybrids
CA2773614A1 (fr) Procede de traitement du cancer par inhibition de l'expression ou l'activite de trim59
US20130253037A1 (en) Aurora a kinase effectors
US7655431B2 (en) Compositions and methods based upon the kinase haspin
WO2003024999A2 (fr) Couplage de la proteine f-box, hcdc4, par la cycline e pour une ubiquitinylation et une degradation
Yap et al. NAC1 Is an Actin-Binding Protein That Is Essential for Effective
KR20100061296A (ko) 인테그린알파５를 이용한 항암제 또는 ｓｉｐ１／ｚｅｂ２ 저해제의 스크리닝 방법

Legal Events

Date Code Title Description
AS Assignment

Owner name: DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KUFE, DONALD W.;REEL/FRAME:012818/0789

Effective date: 20020301

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR, MARY

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:DANA-FARBER CANCER INSTITUTE;REEL/FRAME:039846/0597

Effective date: 20160923